Dermira Inc. (NASDAQ:DERM) CFO Andrew Guggenhime sold 10,000 shares of the business’s stock in a transaction on Monday, September 12th. The stock was sold at an average price of $32.53, for a total value of $325,300.00. Following the sale, the chief financial officer now owns 15,116 shares of the company’s stock, valued at approximately $491,723.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Andrew Guggenhime also recently made the following trade(s):

  • On Thursday, August 11th, Andrew Guggenhime sold 10,000 shares of Dermira stock. The stock was sold at an average price of $31.02, for a total value of $310,200.00.
  • On Monday, July 11th, Andrew Guggenhime sold 10,000 shares of Dermira stock. The stock was sold at an average price of $30.15, for a total value of $301,500.00.

Shares of Dermira Inc. (NASDAQ:DERM) opened at 35.03 on Tuesday. The company’s market cap is $1.24 billion. The company has a 50-day moving average price of $32.28 and a 200-day moving average price of $28.36. Dermira Inc. has a 12-month low of $17.42 and a 12-month high of $35.75.

Dermira (NASDAQ:DERM) last posted its earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.89) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.86) by $0.03. On average, analysts predict that Dermira Inc. will post ($3.39) earnings per share for the current year.

A number of equities research analysts have recently weighed in on DERM shares. Zacks Investment Research upgraded Dermira from a “sell” rating to a “hold” rating in a research report on Tuesday, June 14th. Leerink Swann reiterated a “buy” rating and issued a $47.00 price objective (up previously from $46.00) on shares of Dermira in a report on Thursday, June 2nd. Wedbush upped their price objective on Dermira from $42.00 to $46.00 and gave the company an “outperform” rating in a report on Thursday, June 2nd. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $46.00 price objective on shares of Dermira in a report on Wednesday, June 22nd. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $41.00.

Several large investors have recently bought and sold shares of the company. BlackRock Inc. increased its stake in Dermira by 1.0% in the first quarter. BlackRock Inc. now owns 49,260 shares of the biopharmaceutical company’s stock valued at $1,018,000 after buying an additional 499 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in Dermira by 3.0% in the first quarter. Goldman Sachs Group Inc. now owns 20,420 shares of the biopharmaceutical company’s stock valued at $422,000 after buying an additional 592 shares in the last quarter. ProShare Advisors LLC increased its stake in Dermira by 3.6% in the second quarter. ProShare Advisors LLC now owns 24,914 shares of the biopharmaceutical company’s stock valued at $729,000 after buying an additional 869 shares in the last quarter. BlackRock Group LTD increased its stake in Dermira by 1.0% in the first quarter. BlackRock Group LTD now owns 197,240 shares of the biopharmaceutical company’s stock valued at $4,079,000 after buying an additional 1,898 shares in the last quarter. Finally, Teachers Advisors Inc. increased its stake in Dermira by 1.9% in the first quarter. Teachers Advisors Inc. now owns 123,531 shares of the biopharmaceutical company’s stock valued at $2,555,000 after buying an additional 2,278 shares in the last quarter. Hedge funds and other institutional investors own 82.46% of the company’s stock.

Dermira Company Profile

Dermira, Inc is a biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated therapies for dermatologic diseases. The Company’s portfolio includes three late-stage product candidates that target unmet needs and market opportunities, such as Cimzia (certolizumab pegol), DRM04 and DRM01.

5 Day Chart for NASDAQ:DERM

Receive News & Ratings for Dermira Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc. and related companies with MarketBeat.com's FREE daily email newsletter.